Kyntra Bio, Inc.

Zacks Investment Research•8/13/2026

Kyntra Bio (KYNB) Reports Q2 Loss, Lags Revenue Estimates

Kyntra Bio (KYNB) came out with a quarterly loss of $4.68 per share versus the Zacks Consensus Estimate of a loss of $3.18. This compares to a loss of $3.38 per share a year ago.

GlobeNewsWire•8/13/2026

Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

SAN FRANCISCO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today reported financial results for the second quarter 2026 and provided an update on the company's recent developments.

Zacks Investment Research•8/3/2026

Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: Should You Buy?

Kyntra Bio (KYNB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Defense World•7/17/2026

Head-To-Head Comparison: Kyntra Bio (NASDAQ:KYNB) and Pharmaxis (OTCMKTS:PXSLY)

GlobeNewsWire•6/11/2026

Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes

SAN FRANCISCO, June 11, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced additional data from the Phase 3 MATTERHORN trial showing improvements in transfusion independence in patients with anemia associated with lower-risk myelodysplastic syndromes (LR-MDS) treated with roxadustat will be presented as a poster at the European Hematology Association (EHA) Congress 2026, taking place June 11-14, 2026 in Stockholm, Sweden.